WHA publishes new community briefing on the Global Hepatitis Report 2024

The World Health Organization has released extensive new data about the growing burden of hepatitis in the Global Hepatitis Report 2024: Action for access in low- and middle-income countries. Hepatitis is now the second deadliest communicable disease. Hepatitis related deaths increased to 1.3 million in 2022 from 1.1 million in 2019 and every day 3,500 people are dying from viral hepatitis. The report also provides an update on progress made since 2019 in improving access to hepatitis service coverage and access to medicines for hepatitis B and C in low- and middle-income countries. 

With the 2030 elimination goal fast approaching, the new data is a key advocacy tool to push governments to meet the targets. WHA has developed a community briefing summarising the key facts and messages from the report to help advocates as they fight for change for people living with hepatitis. 

More than 300 million people live with hepatitis globally with 2.2 million people newly infected in 2022. While we are currently off track, there is a window of opportunity for action in 2024 – 2026. Meeting the global hepatitis elimination targets by 2030 will result in 2.85 million lives saved and 9.5 million new infections and 2.1 million cancer cases prevented.  

There is no time to waste, it’s time for action. 

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close